Lumida
/NVAX
⌘K
Novavax Inc

Novavax Inc

NVAX
$8.21USD-0.36%-0.03 today

MARKET CAP

1.4B

P/E (TTM)

FWD P/E

DAY RANGE

$8 – $8

52W RANGE

$6
$12

AI Summary

Stalk
TrimMedium

NVAX remains in a Stage 4 decline with active lower highs & lower lows and a medium-term bearish bias. Price is trading below declining EMAs in an extreme oversold context, making immediate selling unfavorable. Execution favors deferring sell orders until rallies into EMA resistance zones provide cleaner entry points.

  • Sanofi partnership triggers $175M milestone payment and ongoing royalties.
  • Pipeline diversifies into C. diff and oncology programs by 2027.
  • Total revenue fell 79% YoY to $140M, signaling sharp decline.
Full analysis →
Insider Trades42 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Mar 7, 2026SellNVAXJames Patrick KellyEVP, CFO and Treasurer5,904$9.98$1.4B-31.41%+32.42%$58.9K-4.33%Trim
Mar 3, 2026SellNVAXRuxandra Draghia-AkliEVP, Research & Development11,313$9.49$1.4B-31.41%+32.42%$107.4K-3.44%Trim
Mar 3, 2026SellNVAXMark J CaseyEVP, Chief Legal Officer11,378$9.49$1.4B-31.41%+32.42%$108.0K-10.79%Trim
Mar 3, 2026SellNVAXJames Patrick KellyEVP, CFO and Treasurer20,850$9.49$1.4B-31.41%+32.42%$197.9K-9.01%Trim
Mar 3, 2026SellNVAXElaine O'HaraEVP, Chief Strategy Officer22,429$9.49$1.4B-31.41%+32.42%$212.9K-8.32%Trim
Mar 3, 2026SellNVAXJohn C JacobsPresident and CEO69,288$9.49$1.4B-31.41%+32.42%$657.5K-11.64%Trim
Mar 1, 2026SellNVAXMark J CaseyEVP, Chief Legal Officer1,214$10.14$1.4B-31.41%+32.42%$12.3K-0.38%Trim
Mar 1, 2026SellNVAXElaine O'HaraEVP, Chief Strategy Officer16,344$10.14$1.4B-31.41%+32.42%$165.7K-3.12%Trim
Mar 1, 2026SellNVAXJames Patrick KellyEVP, CFO and Treasurer28,366$10.14$1.4B-31.41%+32.42%$287.6K-5.53%Trim
Mar 1, 2026SellNVAXJohn C JacobsPresident and CEO38,450$10.14$1.4B-31.41%+32.42%$389.9K-3.25%Trim
Jan 23, 2026SellNVAXJohn C JacobsPresident and CEO39,132$9.17$1.4B-31.41%+32.42%$358.8K-17.79%Trim
Dec 11, 2025SellNVAXMark J CaseyEVP, Chief Legal Officer12,713$6.69$1.4B-31.41%+32.42%$85.0K-10.98%Trim
Nov 11, 2025SellNVAXRuxandra Draghia-AkliSection 166,048$7.40$1.4B-31.41%+32.42%$44.8K-14.14%Trim
Mar 7, 2025SellNVAXJames Patrick KellyEVP, CFO and Treasurer5,904$8.34$1.4B-31.41%+32.42%$49.2K-6.76%Trim
Mar 7, 2025SellNVAXJohn TrizzinoPresident and COO13,954$8.34$1.4B-31.41%+32.42%$116.4K-12.58%Trim
Mar 1, 2025SellNVAXMark J CaseyEVP, Chief Legal Officer1,214$8.33$1.4B-31.41%+32.42%$10.1K-2.95%Trim
Mar 1, 2025SellNVAXElaine O'HaraEVP, Chief Strategy Officer16,344$8.33$1.4B-31.41%+32.42%$136.1K-6.76%Trim
Mar 1, 2025SellNVAXJohn TrizzinoPresident and COO23,185$8.33$1.4B-31.41%+32.42%$193.1K-13.46%Trim
Mar 1, 2025SellNVAXJames Patrick KellyEVP, CFO and Treasurer28,337$8.33$1.4B-31.41%+32.42%$236.0K-13.58%Trim
Mar 1, 2025SellNVAXJohn C JacobsPresident and CEO38,451$8.33$1.4B-31.41%+32.42%$320.3K-11.25%Trim
Jan 23, 2025SellNVAXJohn C JacobsPresident and CEO38,873$9.55$1.4B-31.41%+32.42%$371.2K-18.17%Trim
Dec 31, 2024SellNVAXJames Patrick KellyEVP, CFO and Treasurer16,906$8.04$1.4B-31.41%+32.42%$135.9K-34.15%Trim
Dec 11, 2024SellNVAXMark J CaseyEVP, Chief Legal Officer12,713$8.82$1.4B-31.41%+32.42%$112.1K-10.11%Trim
Aug 19, 2024SellNVAXJohn TrizzinoEVP, CCO and CBO317$13.90$1.4B-31.41%+32.42%$4.4K-1.11%Trim
Aug 16, 2024BuyNVAXJames Patrick KellyEVP, CFO and Treasurer3,590$12.96$1.4B-31.41%+32.42%$46.5K+3.95%Trim
Jun 17, 2024SellNVAXFilip DubovskyPresident, R&D27,808$10.32$1.4B-31.41%+32.42%$287.1K+0.00%Trim
May 14, 2024SellNVAXFilip DubovskyPresident, R&D66,964$11.87$1.4B-31.41%+32.42%$794.6K-13.79%Trim
Mar 10, 2024SellNVAXJohn TrizzinoPresident and COO2,226$5.45$1.4B-31.41%+32.42%$12.1K-6.40%Trim
Mar 10, 2024SellNVAXJames Patrick KellyEVP, CFO and Treasurer2,226$5.45$1.4B-31.41%+32.42%$12.1K-11.06%Trim
Mar 10, 2024SellNVAXFilip DubovskyPresident, R&D2,597$5.45$1.4B-31.41%+32.42%$14.2K-3.48%Trim
Mar 7, 2024SellNVAXJames Patrick KellyEVP, CFO and Treasurer5,905$5.61$1.4B-31.41%+32.42%$33.1K-7.74%Trim
Mar 7, 2024SellNVAXFilip DubovskyPresident, R&D9,392$5.61$1.4B-31.41%+32.42%$52.7K-12.83%Trim
Mar 7, 2024SellNVAXJohn TrizzinoEVP, CCO and CBO13,955$5.61$1.4B-31.41%+32.42%$78.3K-35.29%Trim
Mar 1, 2024BuyNVAXElaine O'HaraEVP, Chief Strategy Officer24,975$5.39$1.4B-31.41%+32.42%$134.6K+24.19%Trim
Jan 23, 2024SellNVAXJohn C JacobsPresident and CEO40,093$4.26$1.4B-31.41%+32.42%$170.8K-16.06%Trim
Dec 14, 2023SellNVAXJohn A Iii HerrmannEVP, Chief Legal Officer700$5.69$1.4B-31.41%+32.42%$4.0K-5.02%Trim
Dec 14, 2023SellNVAXJohn TrizzinoEVP, CCO and CBO773$5.69$1.4B-31.41%+32.42%$4.4K-6.76%Trim
Dec 14, 2023BuyNVAXFilip DubovskyPresident, R&D4,201$5.69$1.4B-31.41%+32.42%$23.9K+1.36%Trim
Nov 5, 2023BuyNVAXFilip DubovskyPresident, R&D2,077$7.06$1.4B-31.41%+32.42%$14.7K+0.69%Trim
Sep 16, 2023BuyNVAXFilip DubovskyPresident, R&D18,752$7.71$1.4B-31.41%+32.42%$144.6K+6.36%Trim
Aug 19, 2023SellNVAXJohn TrizzinoEVP, CCO and CBO317$7.14$1.4B-31.41%+32.42%$2.3K-2.94%Trim
Aug 16, 2023SellNVAXJames Patrick KellyEVP, CFO and Treasurer1,143$7.13$1.4B-31.41%+32.42%$8.1K-14.12%Trim